Gilead Shares Tick Higher After FDA Clears First Therapy for Chronic HDV
Gilead Sciences shares rose 2.5% on Friday following U.S. Food and Drug Administration approval of Hepcludex (bulevirtide-gmod) injection for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. The drug is the first FDA-approved therapy for chronic HDV, and its efficacy was demonstrated in the ph…